CR20140256A - Inhibitor de cetp de oxazolidinona bicíclico fusionado - Google Patents

Inhibitor de cetp de oxazolidinona bicíclico fusionado

Info

Publication number
CR20140256A
CR20140256A CR20140256A CR20140256A CR20140256A CR 20140256 A CR20140256 A CR 20140256A CR 20140256 A CR20140256 A CR 20140256A CR 20140256 A CR20140256 A CR 20140256A CR 20140256 A CR20140256 A CR 20140256A
Authority
CR
Costa Rica
Prior art keywords
cetp inhibitor
fusion
bicyclic oxazolidinone
fusion bicyclic
oxazolidinone cetp
Prior art date
Application number
CR20140256A
Other languages
English (en)
Inventor
Pengcheng Patrick Shao
Feng Ye
Petr Vachal
Deyou Sha
Revathi Reddy Katipally
Jian Liu
Wanying Sun
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CR20140256A publication Critical patent/CR20140256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos que tienen la estructura de Fórmula I, incluyendo sales farmacéuticamente aceptables de los compuestos, son inhibidores de CETP y son útiles para elevar el colesterol HDL, reducir el colesterol LDL y para tratar o prevenir aterosclerosis.
CR20140256A 2011-10-28 2014-05-28 Inhibitor de cetp de oxazolidinona bicíclico fusionado CR20140256A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161552592P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
CR20140256A true CR20140256A (es) 2014-07-15

Family

ID=47143312

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140256A CR20140256A (es) 2011-10-28 2014-05-28 Inhibitor de cetp de oxazolidinona bicíclico fusionado

Country Status (41)

Country Link
US (2) US8871738B2 (es)
EP (1) EP2771345B1 (es)
JP (1) JP5658427B2 (es)
KR (1) KR101686308B1 (es)
CN (1) CN103958524B (es)
AR (1) AR088565A1 (es)
AU (1) AU2012328759B2 (es)
BR (1) BR112014010204A2 (es)
CA (1) CA2852743C (es)
CL (1) CL2014001090A1 (es)
CO (1) CO6940419A2 (es)
CR (1) CR20140256A (es)
CY (1) CY1118464T1 (es)
DK (1) DK2771345T3 (es)
DO (1) DOP2014000086A (es)
EA (1) EA026123B1 (es)
EC (1) ECSP14002458A (es)
ES (1) ES2604953T3 (es)
GE (1) GEP20166434B (es)
HR (1) HRP20161541T1 (es)
HU (1) HUE030568T2 (es)
IL (1) IL232130A (es)
IN (1) IN2014CN03073A (es)
JO (1) JO3210B1 (es)
LT (1) LT2771345T (es)
MA (1) MA35643B1 (es)
ME (1) ME02557B (es)
MX (1) MX345222B (es)
NI (1) NI201400034A (es)
PE (1) PE20141230A1 (es)
PH (1) PH12014500890A1 (es)
PL (1) PL2771345T3 (es)
PT (1) PT2771345T (es)
RS (1) RS55420B1 (es)
SG (1) SG11201401884PA (es)
SI (1) SI2771345T1 (es)
TN (1) TN2014000158A1 (es)
TW (1) TWI601731B (es)
UA (1) UA114612C2 (es)
WO (1) WO2013063217A1 (es)
ZA (2) ZA201403091B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
ES2623759T3 (es) 2010-10-29 2017-07-12 Merck Sharp & Dohme Corp. Oxazolidinonas sustituidas con amina cíclica como inhibidores de CETP
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9717714B2 (en) 2012-12-19 2017-08-01 Merck Sharp & Dohme Corp. Spirocyclic CETP inhibitors
EP2934519B1 (en) 2012-12-20 2021-05-12 Merck Sharp & Dohme Corp. Therapeutic thiazolidinone compounds
WO2014119947A1 (en) * 2013-01-31 2014-08-07 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2015017302A2 (en) 2013-07-30 2015-02-05 Merck Sharp & Dohme Corp. Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
EP3038465B1 (en) * 2013-08-30 2021-10-06 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
US9688630B2 (en) 2013-10-10 2017-06-27 Merck Sharp & Dohme Corp. 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
CN105814064A (zh) * 2013-12-17 2016-07-27 默沙东公司 作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类
DK3102212T3 (en) * 2014-02-05 2019-02-11 Dezima Pharma B V Cholesteryl ester transfer protein (CETP) inhibitors and pharmaceutical compositions comprising the inhibitor for use in the treatment or prevention of cardiovascular disease
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX373150B (es) 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
WO2016018729A1 (en) 2014-07-29 2016-02-04 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
WO2016067194A1 (en) * 2014-10-27 2016-05-06 Sun Pharmaceutical Industries Limited Process for the preparation of anacetrapib and an intermediate thereof
WO2016084949A1 (ja) * 2014-11-28 2016-06-02 興和株式会社 医薬
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3307672A4 (en) * 2015-06-12 2019-04-10 Rhodia Operations HYBRIDNANOPARTICLES WITH DENDRONES, METHOD FOR PRODUCING SUCH HYBRIDNANOPARTICLES AND USES THEREOF
EP3322420B1 (en) 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
CN106432053A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种尼拉帕布中间体4‑(3s‑哌啶‑3‑基)溴苯的制备方法
CN106432058A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种Niraparib中间体4‑（3S‑哌啶‑3‑基）苯胺的制备方法
CN111285894B (zh) * 2018-12-10 2021-03-05 北京天一绿甫医药科技有限公司 用于制备软海绵素类化合物的中间体及其制备方法
CN110639018B (zh) * 2019-11-14 2020-06-26 牡丹江医学院 一种防治老年性高血压的药物组合物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2004019869A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004020408A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
JP2007504285A (ja) 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
ATE426605T1 (de) 2003-06-12 2009-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1656140A4 (en) 2003-08-13 2009-03-04 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
CN1938320A (zh) * 2004-03-26 2007-03-28 伊莱利利公司 用于治疗异常脂肪血症的化合物和方法
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1942428A (zh) * 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
JP2009521458A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション トロンビン受容体アンタゴニストとしてのオキサゾロイソキノリン誘導体
EP1973889B1 (en) * 2005-12-30 2016-08-24 Merck Sharp & Dohme Corp. Cetp inhibitors
EP1971595B1 (en) 2005-12-30 2013-10-16 Merck Sharp & Dohme Corp. Cetp inhibitors
US7915271B2 (en) 2005-12-30 2011-03-29 Merck Sharp & Dohme Corp. 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
WO2010039474A1 (en) * 2008-10-01 2010-04-08 Merck Sharp & Dohme Corp. Prodrugs of oxazolidinone cetp inhibitors
WO2011028395A1 (en) 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Pyridyl oxazolidinone cetp inhibitor
ES2623759T3 (es) 2010-10-29 2017-07-12 Merck Sharp & Dohme Corp. Oxazolidinonas sustituidas con amina cíclica como inhibidores de CETP
EP2844252B1 (en) 2012-05-02 2016-11-30 Merck Sharp & Dohme Corp. Cyclic amine substituted heterocyclic compounds as cetp inhibitors

Also Published As

Publication number Publication date
TWI601731B (zh) 2017-10-11
HUE030568T2 (en) 2017-05-29
GEP20166434B (en) 2016-02-10
DK2771345T3 (en) 2017-01-09
CL2014001090A1 (es) 2014-08-01
CO6940419A2 (es) 2014-05-09
JP2014532652A (ja) 2014-12-08
KR101686308B1 (ko) 2016-12-13
ECSP14002458A (es) 2015-11-30
PT2771345T (pt) 2016-11-30
BR112014010204A2 (pt) 2017-05-09
JO3210B1 (ar) 2018-03-08
PL2771345T3 (pl) 2017-04-28
US20140378493A1 (en) 2014-12-25
HK1195558A1 (zh) 2014-11-14
CA2852743C (en) 2016-08-02
US20130109649A1 (en) 2013-05-02
AR088565A1 (es) 2014-06-18
EA026123B1 (ru) 2017-03-31
IL232130A0 (en) 2014-05-28
SI2771345T1 (sl) 2016-12-30
TN2014000158A1 (en) 2015-09-30
MX2014005074A (es) 2014-08-01
RS55420B1 (sr) 2017-04-28
IL232130A (en) 2017-07-31
NI201400034A (es) 2014-10-10
ES2604953T3 (es) 2017-03-10
AU2012328759A1 (en) 2014-05-01
EA201490889A1 (ru) 2015-05-29
ME02557B (me) 2017-02-20
DOP2014000086A (es) 2014-07-15
WO2013063217A1 (en) 2013-05-02
PE20141230A1 (es) 2014-09-28
TW201321388A (zh) 2013-06-01
UA114612C2 (uk) 2017-07-10
MX345222B (es) 2017-01-20
US8871738B2 (en) 2014-10-28
EP2771345A1 (en) 2014-09-03
PH12014500890A1 (en) 2014-06-09
AU2012328759B2 (en) 2015-09-10
SG11201401884PA (en) 2014-09-26
JP5658427B2 (ja) 2015-01-28
HRP20161541T1 (hr) 2016-12-30
CN103958524A (zh) 2014-07-30
US9346825B2 (en) 2016-05-24
ZA201406833B (en) 2016-02-24
CA2852743A1 (en) 2013-05-02
IN2014CN03073A (es) 2015-07-31
MA35643B1 (fr) 2014-11-01
EP2771345B1 (en) 2016-09-21
LT2771345T (lt) 2016-11-25
CY1118464T1 (el) 2017-07-12
CN103958524B (zh) 2016-04-06
KR20140094571A (ko) 2014-07-30
NZ625435A (en) 2015-12-24
ZA201403091B (en) 2015-04-29

Similar Documents

Publication Publication Date Title
CR20140256A (es) Inhibitor de cetp de oxazolidinona bicíclico fusionado
UY39630A (es) Inhibidores de bromodominios
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CR20120418A (es) Inhibidores de virus flaviviridae
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2020005498A (es) Inhibidores de cdk.
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
CL2013002114A1 (es) Compuestos de esteres de arilalquilo de 4 - amino - 6 - (fenil sustituido) picolinatos y 6 - amino- 2 - (fenil sustituido) - 4 - pirimidincarboxilatos; composicion herbicida que comprende dichos compuestos; metodo para el control de vegetacion indeseable.
UA107954C2 (xx) Заміщені піролідин-2-карбоксаміди
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
ECSP12012104A (es) Inhibidores de virus flaviviridae
MX2016002178A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
CR20140151A (es) Compuestos de piperidina útiles para el tratamiento de enfermedades neurodegenerativas-1-arilcarbolino-4-oxya
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CO6791602A2 (es) Métodos y sistemas para el tratamiento de pozos
BR112014004937A2 (pt) método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr
UY34315A (es) ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ?
MX372739B (es) Metodos y composiciones para inhibir cnksr1.
CY1120666T1 (el) Μεθοδος για τη θεραπεια ελλειμματων οστικου κενου
CO6821965A2 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2